8-K: SELLAS Raises $31M via Warrant Exercise, Issues New Warrants

SELLAS Life Sciences Group secured approximately $31 million in gross proceeds by inducing existing warrant holders to exercise their warrants, simultaneously issuing new warrants.

Summary

• SELLAS Life Sciences Group entered into a Warrant Inducement Agreement on October 24, 2025, with holders of certain existing warrants.
• The agreement induced holders to cash exercise warrants issued in March 2024 (6,514,658 shares at $1.535 per share) and August 2024 (15,849,056 shares at $1.325 per share).
• This transaction generated aggregate gross proceeds of approximately $31.0 million for the company.
• In consideration for the exercise of these existing warrants, SELLAS agreed to issue new registered warrants to purchase up to 22,363,714 shares of common stock.
• The new warrants have an exercise price of $2.00 per share, are immediately exercisable, and will expire five years from their issuance date.
• The company engaged A.G.P./Alliance Global Partners and Maxim Group LLC as financial advisors, agreeing to pay them an aggregate fee of 5.75% of the gross proceeds and reimburse legal expenses up to $60,000.
• The proceeds from the exercise of the existing warrants are intended to settle outstanding litigation.
• The closing of this transaction is expected to occur on or about October 28, 2025.

Sentiment

Score: 7

Explanation: The capital raise of $31 million is a significant positive, especially with the stated use for settling litigation, which removes a potential overhang. However, the issuance of an equal number of new warrants at a higher exercise price introduces future dilution risk. The restrictions on future equity sales for 75 days and variable rate transactions for 12 months also limit immediate financing flexibility.

Positives

• Secured approximately $31.0 million in gross cash proceeds, strengthening the company's liquidity.
• The capital raised is designated for settling outstanding litigation, which could remove a significant financial and operational overhang.
• The issuance of new warrants, exercisable immediately, provides a potential source of future capital if exercised.

Negatives

• The transaction involves significant potential dilution from the issuance of up to 22,363,714 new warrants, which is 100% of the shares issued from the exercised existing warrants.
• Incurred substantial financial advisory fees of approximately $1.78 million (5.75% of $31.0 million) plus up to $60,000 in legal expenses.
• The company is subject to restrictions for 75 days on issuing or announcing the issuance of common stock or equivalents, and for 12 months on effecting Variable Rate Transactions, limiting future financing flexibility.

Risks

• Risks and uncertainties associated with oncology product development and the clinical success of product candidates.
• Uncertainty regarding regulatory approval for the company's therapies.
• General risks and uncertainties affecting SELLAS and its development programs, as detailed in its Annual Report on Form 10-K.
• Potential for further dilution if the newly issued inducement warrants are exercised in the future.

Future Outlook

The company plans to host a virtual R&D Day on October 29, 2025, to discuss the unmet medical need and evolving treatment landscape for acute myeloid leukemia (AML). The company is also subject to restrictions on future equity issuances for 75 days and prohibitions on Variable Rate Transactions for 12 months following the agreement date.

Management Comments

• SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
• SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
• GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.
• The company is also developing SLS009 (tambiciclib) potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors.
• Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.

Industry Context

SELLAS operates in the biopharmaceutical sector, specifically focusing on oncology with late-stage clinical development for cancer indications like acute myeloid leukemia (AML). The upcoming R&D Day highlights its continued focus on addressing unmet medical needs in this therapeutic area, aligning with ongoing innovation in cancer treatment.

Legal Proceedings

• Proceeds from the exercise of the Existing Warrants will be used to settle outstanding litigation.

Stakeholder Impact

• Shareholders: Experience immediate dilution from the exercised warrants and face potential future dilution from the newly issued warrants. Benefit from improved financial stability and the resolution of outstanding litigation.
• Creditors: Benefit from the company's strengthened financial position, potentially reducing credit risk.
• Employees/Management: Enhanced financial stability supports ongoing operations and development programs, providing greater job security and resources for strategic initiatives.

Next Steps

• Closing of the transaction is expected to occur on or about October 28, 2025.
• The company will host a virtual R&D Day on October 29, 2025, at 10:00 AM ET to discuss acute myeloid leukemia (AML).
• The company is prohibited from certain equity issuances for 75 days following the agreement date.
• The company is prohibited from effecting Variable Rate Transactions for 12 months following the agreement date.

Key Dates

Recommendation

While the $31 million capital raise and the use of proceeds to settle litigation are positive for immediate financial stability and risk reduction, the significant potential dilution from the newly issued warrants at a higher exercise price creates uncertainty. The restrictions on future capital raising methods also limit flexibility. Investors should hold to assess the impact of the dilution and the company's progress in its R&D pipeline, particularly following the upcoming R&D Day, before making further investment decisions.

Keywords

SELLAS Life Sciences, SLS, Warrant Exercise, Capital Raise, Biopharmaceutical, Oncology, AML, Equity Financing, Warrants, SEC Filing